Neoleukin Therapeutics, Inc.
NLTX
Price:
$3.49
Market Cap:
$8.20M
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2014-03-07
Stock Exchange
NASDAQ
Ticker
NLTX
The ROE as of September 2024 (TTM) for Neoleukin Therapeutics, Inc. (NLTX) is -47.64%
According to Neoleukin Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -47.64%. This represents a change of 307.57% compared to the average of -11.69% of the last 4 quarters.
Neoleukin Therapeutics, Inc. (NLTX) Historical ROE (quarterly & annually)
How has NLTX ROE performed in the past?
The mean historical ROE of Neoleukin Therapeutics, Inc. over the last ten years is -45.46%. The current -47.64% ROE has changed 4.79% with respect to the historical average. Over the past ten years (40 quarters), NLTX's ROE was at its highest in in the December 2013 quarter at 3.36%. The ROE was at its lowest in in the September 2019 quarter at -88.42%.
Average
-45.46%
Median
-46.23%
Minimum
-86.41%
Maximum
-13.05%
Neoleukin Therapeutics, Inc. (NLTX) ROE by Quarter and Year
Discovering the peaks and valleys of Neoleukin Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 213.29%
Maximum Annual ROE = -13.05%
Minimum Annual Increase = -463.78%
Minimum Annual ROE = -86.41%
| Year | ROE | Change |
|---|---|---|
| 2022 | -59.38% | 45.23% |
| 2021 | -40.89% | 213.29% |
| 2020 | -13.05% | -73.37% |
| 2019 | -49.01% | 12.75% |
| 2018 | -43.46% | -14.36% |
| 2017 | -50.75% | 98.41% |
| 2016 | -25.58% | 26.86% |
| 2015 | -20.16% | -69.40% |
| 2014 | -65.90% | -23.73% |
| 2013 | -86.41% | -463.78% |
Neoleukin Therapeutics, Inc. (NLTX) Average ROE
How has NLTX ROE performed in the past?
The current ROE of Neoleukin Therapeutics, Inc. (NLTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-37.77%
5-year avg
-41.16%
10-year avg
-45.46%
Neoleukin Therapeutics, Inc. (NLTX) ROE vs. Peers
How is NLTX’s ROE compared to its peers?
Neoleukin Therapeutics, Inc.’s ROE is greater than CytomX Therapeutics, Inc. (-27.44%), less than Spero Therapeutics, Inc. (20.70%), greater than Instil Bio, Inc. (-55.57%), greater than NextCure, Inc. (-57.63%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Achilles Therapeutics plc (-47.36%), greater than Nuvation Bio Inc. (-98.79%),
| Company | ROE | Market cap |
|---|---|---|
| -27.44% | $93.74M | |
| 20.70% | $71.07M | |
| -55.57% | $92.68M | |
| -57.63% | $39.73M | |
| -121.55% | $107.81M | |
| -47.36% | $29.58M | |
| -98.79% | $692.60M |
Build a custom stock screener for Neoleukin Therapeutics, Inc. (NLTX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neoleukin Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Neoleukin Therapeutics, Inc. (NLTX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Neoleukin Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Neoleukin Therapeutics, Inc.'s ROE?
How is the ROE calculated for Neoleukin Therapeutics, Inc. (NLTX)?
What is the highest ROE for Neoleukin Therapeutics, Inc. (NLTX)?
What is the 3-year average ROE for Neoleukin Therapeutics, Inc. (NLTX)?
What is the 5-year average ROE for Neoleukin Therapeutics, Inc. (NLTX)?
How does the current ROE for Neoleukin Therapeutics, Inc. (NLTX) compare to its historical average?